LINCOTEK
21.3.2022 14:02:44 CET | Business Wire | Press release
Global contract manufacturer Lincotek announced today that it has signed an agreement to acquire a majority stake in Italy-based Pegasus’ medical division. The Alaria family will remain fully involved in the business, with Alberto Alaria taking the position of Managing Director of the new entity.
The move will further strengthen the Medical Division of Lincotek Group , which is continuing its global investment program to respond to ever-more demanding customer requirements in terms of integrated solutions. Through new technologies and automation, the company is addressing the growing interest of the orthopedic device market in an automated forging service, increasing efficiency along the supply chain, setting new standards around quality and reliability and further reducing lead time.
The investment represents an important addition to an already comprehensive set of capabilities that Lincotek Medical has in-house and enhances the company’s competitive edge, adding unique, state-of- the-art capabilities in the forging field.
Established in 2007 in Torino, northern Italy, Pegasus decided in 2019 to expand its innovative forging processes into the medical market. The brand-new facility - with a surface area of around 3,000 sqm - is completely dedicated to orthopedic applications, being ISO 13485 certified and having an ISO 17025 certified internal laboratory. Lincotek’s forging offers a unique level of automation through the manufacturing process ensuring state-of-the-art product quality, total process control and repeatability.
The fully robotized forging line - which allows the manufacture of high-quality forged implantable parts to customer specifications – is the flagship of a complete production service of forged components. Its capabilities are combined with a state-of-the-art, AMS-2750-compliant heat treatment furnace ; automated pickling line and liquid penetrant inspection unit ; laboratory equipment; internal mold manufacturing; robotized deburring and polishing unit; and computerized dimensional control.
Lincotek Medical will therefore offer a new, impressive, high-volume capacity, through single service or fully-integrated solutions to support OEMs with a strategic long-term partnership.
Winfried Schaller, CEO of Lincotek Group commented: “With the acquisition of the majority stake in Pegasus medical division, Lincotek Medical is in a stronger position than ever before to support orthopedic OEMs. By combining this impressive forging service with our existing offering, we are able to help customers stay competitive and get to market even faster. It really is a new world of advanced automation and productivity.”
Speaking for Pegasus, Alberto Alaria, the company’s Managing Director, said: “Pegasus is proud to enter into partnership with Lincotek Group which represents a great opportunity to grow our presence in the forged medical implants market with the offering of high-quality products. The new synergies and product integration that will be generated moves us a step ahead and creates the possibility of further strengthening the cooperation with our valued customers.”
Bringing this full suite of processes in-house, orthopedic OEMs can now rely on a well-established partner, which has broad capabilities and brings together the core competencies of R&D, product design, regulatory affairs, and manufacturing all under one roof, keeping focus on their core competencies.
About Lincotek
Lincotek, headquartered in Rubbiano, Parma - Italy, is a global contract manufacturer for services in niche markets including Industrial Gas Turbines, Aviation and Medical Device applications, as well as a leading manufacturer of industrial coating equipment and one of the most respected producers in the Additive Manufacturing field. The Group is family-owned and has more than 1,300 employees located in 17 production facilities across Europe, North America and Asia.
About Pegasus
Established in Favria, Torino (Italy) in 2007 on a 100,000 sqm site, of which 20,000 is covered, PEGASUS has forging, heat treating, machining and NDT inspection capabilities for the production of forged and rolled components for Industrial and Medical purposes.
For more information, please visit lincotek.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220321005021/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Bolivarian Republic of Venezuela Announces the Initiation of a Comprehensive Public Debt Restructuring Process13.5.2026 22:08:00 CEST | Press release
The Bolivarian Republic of Venezuela announces today its decision to initiate a comprehensive restructuring of its external public debt obligations. CONTEXT & RATIONALE Over the past decade, Venezuela's economy has been severely impacted by external shocks – from the end of the commodity super-cycle to foreign sanctions and COVID-19 – resulting in a sharp economic contraction, a protracted default since 2017, and a ballooning of public sector liabilities. The country nonetheless possesses a strong economic potential, including unique hydrocarbon and mineral endowments. A recovery is underway, and Venezuela is committed to accelerating it through a comprehensive reform agenda in support of growth, fiscal sustainability, monetary stabilization, and enhanced governance. Restoring public debt sustainability is central to this agenda: the current debt overhang constrains external financing, limits public investment capacity, and prevents full re-engagement with the international financial s
Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise13.5.2026 21:00:00 CEST | Press release
Proposed acquisition extends Boomi’s AI gateway capabilities, enabling enterprises to govern massive volumes of traffic for production-ready AI Boomi, the data activation company for AI, today announced it has signed a letter of intent to acquire Lunar.dev, an innovator in AI and MCP gateway. The proposed acquisition is expected to enrich the Boomi Enterprise Platform and Boomi Connect with advanced capabilities to govern and scale AI usage across enterprise systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513850557/en/ Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise As organizations move from AI experimentation to production, controlling how agents and AI applications interact with LLMs at scale has become critical. Lunar.dev addresses this need with an AI gateway that delivers granular, policy-driven control over AI interactions, with the visibility, securi
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma13.5.2026 19:27:00 CEST | Press release
BEQALZI is a foundational BCL2 inhibitor designed for greater potency and selectivity, with potential to improve efficacy, tolerability, and convenience versus others in the classApproval of BEQALZI marks the first new BCL2 inhibitor approved in a decade in the U.S. and the only BCL2 inhibitor approved in MCL, aiming to set a new standard of innovation BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™(bee-KAHL-zee; sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. BEQALZI was designed to enhance BCL2 inhibition—with greater potency, selectivity, and a pharmacologic profile with potential to improve efficacy, tolerability, a
Boomi Unveils Innovations That Power the Agentic Enterprise13.5.2026 16:30:00 CEST | Press release
Orchestration capabilities simplify workflows, while advanced agent connectivity and an enhanced context layer activate data and scale AI Boomi, the data activation company for AI, today announced a major expansion of the Boomi Enterprise Platform at Boomi World 2026, introducing new capabilities across orchestrated agentic workflows, agentic engineering, governed agent connectivity, grounded agent context, and localized agent infrastructure. Together, these innovations are designed to power the agentic enterprise — where agents and humans work together to drive action and operationalize AI at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513996223/en/ Boomi Unveils Innovations That Power the Agentic Enterprise The enterprise has reached a defining moment as AI becomes the primary interface for work and MCP emerges as the new standard. While the shift toward a headless, agentic enterprise is inevitable, this visio
Boomi and Red Hat Collaborate on Production-Ready Agentic AI13.5.2026 16:30:00 CEST | Press release
Companies team to deliver a unified, enterprise-scale agentic stack to help organizations with managing data sovereignty and optimizing AI costs Boomi, the data activation company for AI, and Red Hat, the world’s leading provider of open source solutions, today announced a strategic collaboration to deliver a single, integrated stack for deploying agentic AI at scale. For many organizations, building production AI today means assembling numerous disconnected vendor choices spanning agent builders, orchestration tools, governance platforms, model providers, integration middleware, and security infrastructure, which can lead to data leaks and unpredictable costs. Boomi and Red Hat are working together to simplify AI innovation for customers by bringing together Boomi’s Agentstudio with the enterprise-grade power of Red Hat AI. This makes it easier for organizations to build agents that solve real business problems while supporting corporate standards for sovereignty, infrastructure flexi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom